FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic CancerThierry Conroy, Jean‐Baptiste Bachet, Laurence Choné et al.|New England Journal of Medicine|2018Cited by 2.8k
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic CancerThierry Conroy, Jean François Seitz, Florence Castan et al.|JAMA Oncology|2022Cited by 322
[Management of adverse effects of targeted therapy toxicities in oncology].Elodie Coquan, Florence Joly, Patrick Henri et al.|PubMed|2012Cited by 3